Cytokinetics, Incorporated
aficamten
non-obstructive hypertrophic cardiomyopathy
Resolved
63days ago
Phase 3 readout · May 5, 2026
What's at stake
Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy are due May 5, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Report topline results from ACACIA-HCM in Q2 2026.”